Overall, the results presented here indicate that the use of molecules modulating cytoskeleton dynamics (LIMK inhibitor, epothilone or NAP), in combination with a classical antipsychotic or antidepressant treatment could be a relevant pharmacological treatment for schizophrenia or major depression. The gene discussed is LIMK1; the disease is major depressive disorder.